GlaxoSmithKline Gross profit (Q1, 2018)4.8 B

GlaxoSmithKline Gross profit margin (Q1, 2018), %66.9%

GlaxoSmithKline Net income (Q1, 2018)759 M

GlaxoSmithKline EBIT (Q1, 2018)1.2 B

GlaxoSmithKline Cash, 31-Mar-20184 B

GlaxoSmithKline EV115.4 B

GlaxoSmithKline revenue was £30.19 b in FY, 2017 which is a 8.2% year over year increase from the previous period.

GlaxoSmithKline revenue breakdown by business segment: 25.7% from Consumer Healthcare, 17.1% from Vaccines and 57.2% from Global Pharmaceuticals

GlaxoSmithKline revenue breakdown by geographic segment: 59.6% from International, 37.3% from US and 3.1% from Other

GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 18.1b | 20.5b | 21.2b | 21.4b | 20.4b | 21.7b | 23.2b | 22.7b | 26.5b | 27.9b | 30.2b |

| 17% | 8% | |||||||||

## Cost of goods sold | 4.0b | 4.7b | 4.6b | 4.5b | 4.3b | 4.8b | 5.0b | 5.3b | 8.6b | 9.3b | 10.3b |

## Gross profit | 14.1b | 15.8b | 16.6b | 16.9b | 16.0b | 16.9b | 18.2b | 17.4b | 17.9b | 18.6b | 19.8b |

| 78% | 77% | 78% | 79% | 79% | 78% | 78% | 77% | 68% | 67% | 66% |

## R&D expense | 3.6b | 4.5b | |||||||||

## General and administrative expense | 9.4b | 9.7b | |||||||||

## Operating expense total | 9.4b | 11.0b | 11.1b | 10.5b | 10.0b | 10.0b | 10.4b | 9.8b | 10.9b | 16.0b | 15.8b |

## EBITDA | 8.7b | 9.3b | |||||||||

| 38% | 35% | |||||||||

## EBIT | 4.7b | 4.7b | 5.6b | 6.4b | 6.1b | 6.9b | 7.8b | 7.6b | 7.0b | 2.6b | 4.1b |

| 26% | 23% | 26% | 30% | 30% | 32% | 34% | 33% | 27% | 9% | 14% |

## Interest expense | 736.0m | 734.0m | |||||||||

## Interest income | 72.0m | 65.0m | |||||||||

## Pre tax profit | 6.0b | 4.5b | 5.5b | 6.3b | 6.1b | 6.7b | 7.8b | 7.5b | 6.6b | 1.9b | 3.5b |

## Income tax expense | (1.7b) | (1.3b) | (1.5b) | (1.7b) | (1.7b) | (1.9b) | (2.3b) | (2.1b) | (1.0b) | 877.0m | 1.4b |

## Net Income | 4.3b | 3.2b | 4.0b | 4.6b | 4.4b | 4.8b | 5.5b | 5.3b | 5.6b | 1.1b | 2.2b |

GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
---|---|---|---|---|

## Revenue | 7.4b | 7.3b | 7.8b | 7.2b |

## Cost of goods sold | 2.5b | 2.6b | 2.7b | 2.4b |

## Gross profit | 4.9b | 4.7b | 5.2b | 4.8b |

| 66% | 64% | 66% | 67% |

## R&D expense | 960.0m | 1.3b | 1.0b | 904.0m |

## General and administrative expense | 2.5b | 2.4b | 2.3b | 2.3b |

## Operating expense total | 3.2b | 4.7b | 3.3b | 3.6b |

## EBIT | 1.7b | (20.0m) | 1.9b | 1.2b |

| 23% | 0% | 24% | 17% |

## Interest expense | 194.0m | 192.0m | 194.0m | 162.0m |

## Interest income | 21.0m | 15.0m | 13.0m | 20.0m |

## Pre tax profit | 1.6b | (178.0m) | 1.7b | 1.1b |

## Income tax expense | 327.0m | (92.0m) | 316.0m | 348.0m |

## Net Income | 1.2b | (86.0m) | 1.4b | 759.0m |

GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 1.3b | 716.0m | 1.1b | 962.0m | 1.2b | 4.2b | 2.0b | 3.4b | 5.5b | 4.9b | 3.8b |

## Accounts Receivable | 3.3b | 3.6b | 3.5b | 3.7b | 3.8b | 4.4b | 4.4b | 4.6b | 4.0b | 6.0b | 6.0b |

## Inventories | 2.3b | 2.1b | 2.1b | 2.1b | 2.2b | 2.2b | 2.4b | 3.1b | 3.9b | 5.1b | 5.6b |

## Current Assets | 11.3b | 10.0b | 10.7b | 12.6b | 13.6b | 13.2b | 11.0b | 13.6b | 15.2b | 16.7b | 15.9b |

## PP&E | 9.2b | 10.1b | 9.8b | 9.5b | 6.8b | 9.9b | 10.5b | 7.8b | 8.9b | 10.8b | 10.9b |

## Goodwill | 6.0b | 5.7b | |||||||||

## Total Assets | 21.6b | 21.9b | 22.3b | 24.0b | 22.6b | 27.2b | 25.6b | 31.0b | 42.1b | 59.1b | 56.4b |

## Accounts Payable | 812.0m | 760.0m | 715.0m | 686.0m | 707.0m | 819.0m | 865.0m | 931.0m | 2.7b | 12.0b | 21.0b |

## Short-term debt | 4.1b | 2.8b | |||||||||

## Current Liabilities | 9.1b | 9.4b | 8.8b | 8.6b | 8.7b | 9.5b | 7.3b | 10.3b | 13.7b | 19.0b | 26.6b |

## Long-term debt | 14.7b | 14.3b | |||||||||

## Non-Current Liabilities | 4.8b | 5.0b | 6.9b | 7.7b | 7.9b | 10.4b | 8.9b | 11.1b | 21.4b | 35.1b | 26.3b |

## Total Debt | 191.0m | 230.0m | 193.0m | 155.0m | 112.0m | 1.1b | 676.0m | 3.5b | 2.8b | 18.8b | 17.1b |

## Total Liabilities | 13.9b | 14.4b | 15.7b | 16.3b | 16.7b | 19.9b | 16.2b | 21.4b | 35.1b | 54.1b | 52.9b |

## Common Stock | 1.3b | 1.3b | |||||||||

## Additional Paid-in Capital | 1.6b | 1.5b | 1.5b | 1.5b | 1.5b | 1.5b | 1.5b | 1.5b | 1.3b | 3.0b | 3.0b |

## Retained Earnings | 4.2b | 703.0m | 1.6b | 2.1b | 1.9b | 2.3b | 2.8b | 2.4b | 1.9b | (5.4b) | (6.5b) |

## Total Equity | 7.7b | 7.5b | 6.6b | 7.7b | 5.9b | 7.3b | 9.4b | 9.6b | 7.0b | 5.0b | 3.5b |

## Debt to Equity Ratio | 0 x | 0 x | 0 x | 0 x | 0 x | 0.2 x | 0.1 x | 0.4 x | 0.4 x | 3.8 x | 4.9 x |

## Debt to Assets Ratio | 0 x | 0 x | 0 x | 0 x | 0 x | 0 x | 0 x | 0.1 x | 0.1 x | 0.3 x | 0.3 x |

## Financial Leverage | 2.8 x | 2.9 x | 3.4 x | 3.1 x | 3.8 x | 3.7 x | 2.7 x | 3.2 x | 6 x | 11.9 x | 16.2 x |

GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
---|---|---|---|---|

## Cash | 4.5b | 4.0b | 4.7b | 4.0b |

## Accounts Receivable | 6.2b | 6.2b | 6.5b | 6.1b |

## Inventories | 5.4b | 5.7b | 5.7b | 5.7b |

## Current Assets | 16.8b | 16.4b | 17.7b | 16.4b |

## PP&E | 10.8b | 10.7b | 10.6b | 10.7b |

## Goodwill | 6.0b | 5.9b | 5.8b | 5.6b |

## Total Assets | 59.2b | 58.2b | 5.9b | 56.2b |

## Accounts Payable | 12.0b | 19.6b | 19.8b | 21.1b |

## Short-term debt | 3.7b | 6.6b | 4.7b | 3.4b |

## Current Liabilities | 18.8b | 28.8b | 27.4b | 26.9b |

## Long-term debt | 14.6b | 12.3b | 14.3b | 14.0b |

## Non-Current Liabilities | 34.9b | 25.0b | 26.5b | 25.6b |

## Total Debt | 18.3b | 18.9b | 19.0b | 17.5b |

## Total Liabilities | 53.6b | 53.8b | 54.0b | 52.6b |

## Common Stock | 1.3b | 1.3b | 1.3b | 1.3b |

## Additional Paid-in Capital | 3.0b | 3.0b | 3.0b | 3.0b |

## Retained Earnings | (4.9b) | (5.9b) | (5.3b) | (6.4b) |

## Total Equity | 5.6b | 4.4b | 4.8b | 3.6b |

## Debt to Equity Ratio | 4.3 x | 3.9 x | 4.9 x | |

## Debt to Assets Ratio | 0.3 x | 3.2 x | 0.3 x | |

## Financial Leverage | 10.6 x | 13.2 x | 1.2 x | 15.6 x |

GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2013 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | 4.3b | 3.2b | 4.0b | 4.6b | 4.4b | 4.8b | 5.5b | 5.3b | 5.6b | 1.1b | 2.2b |

## Depreciation and Amortization | 2.0b | 2.9b | |||||||||

## Accounts Receivable | (188.0m) | (287.0m) | |||||||||

## Inventories | 70.0m | (461.0m) | |||||||||

## Accounts Payable | 96.0m | 11.0m | |||||||||

## Cash From Operating Activities | 5.4b | 6.5b | 7.3b | 7.0b | 6.5b | 6.0b | 4.4b | 6.2b | 7.2b | 6.5b | 6.9b |

## Purchases of PP&E | (1.5b) | (1.5b) | |||||||||

## Cash From Investing Activities | (1.3b) | (1.4b) | |||||||||

## Short-term Borrowings | 148.0m | (3.2b) | |||||||||

## Long-term Borrowings | (18.0m) | (23.0m) | |||||||||

## Dividends Paid | 56.0m | 2.4b | 2.4b | 2.4b | 2.4b | 2.4b | 2.6b | 2.8b | 3.7b | (4.8b) | (3.9b) |

## Cash From Financing Activities | (546.0m) | (1.4b) | (1.6b) | (276.0m) | (454.0m) | (2.9b) | (4.8b) | (1.7b) | (6.3b) | (6.4b) | (6.4b) |

## Net Change in Cash | 822.0m | 612.0m | 405.0m | 27.0m | 257.0m | 1.4b | 2.0b | 1.4b | 1.5b | (1.2b) | (905.0m) |

## Interest Paid | (732.0m) | (781.0m) | |||||||||

## Income Taxes Paid | (1.6b) | (1.3b) |

GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 |
---|---|---|---|---|

## Net Income | 1.2b | 1.1b | 2.5b | 759.0m |

## Cash From Operating Activities | 1.1b | 2.2b | 4.0b | 863.0m |

## Purchases of PP&E | (260.0m) | (639.0m) | (1.0b) | (258.0m) |

## Cash From Investing Activities | (199.0m) | (646.0m) | (1.1b) | (371.0m) |

## Short-term Borrowings | (528.0m) | 386.0m | (1.4b) | 701.0m |

## Long-term Borrowings | (3.0m) | (13.0m) | (18.0m) | (7.0m) |

## Dividends Paid | (925.0m) | (2.0b) | (3.0b) | (929.0m) |

## Cash From Financing Activities | (1.5b) | (2.5b) | (3.1b) | (283.0m) |

## Net Change in Cash | (564.0m) | (968.0m) | (182.0m) | 209.0m |

## Income Taxes Paid | (206.0m) | (557.0m) | (893.0m) | (198.0m) |

GBP | Y, 2018 |
---|---|

## EV/EBIT | 93 x |

## EV/CFO | 133.7 x |

## Debt/Equity | 4.9 x |

## Debt/Assets | 0.3 x |

## Financial Leverage | 15.6 x |

Report incorrect company information

GlaxoSmithKline's Unique Visitors was reported to be 1.8 m in FY, 2015.

FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | |
---|---|---|---|---|

## Consumer Healthcare Products Produced | 6.20 b | |||

## Countries | 100 | 100 | 100 | |

## Manufacturing Facilities | 57 | 54 | 87 | |

## Markets | 150 | 150 | 150 | |

## New Product Launches | 50 | 40 | 30 | |

## Partners | 1.50 k | 1.50 k | 2 k | |

## Unique Visitors | 1.80 m | |||

## Vaccine Doses Delivered per Day | 2 m | |||

## Vaccines | 798 m | |||

## Volume of Medicines Produced | 1.90 b |

Report incorrect company information